Biogen Critics Are Not Impressed By Aduhelm Price Cut

By Gabrielle Wanneh / December 20, 2021 at 4:57 PM

Critics of Biogen are not impressed by the company’s plan to cut the annual price of its Alzheimer’s drug Aduhelm from $56,000 to $28,000.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.